Associate Director of Brand and Creative Services
Department: Marketing and Communications
Paige Butler
Associate Director of Distinguished Events
Department: Development
Erin Parry, MD, PhD
Researcher Spotlight: Erin Parry, MD, PhD DANA-FARBER CANCER INSTITUTE Dr. Parry’s research is centered at the intersection of genomics and cancer immunotherapy, with a focus on B cell lymphomas. Her LRF research project is aimed at understanding the processes that…
Wen-Hsuan Wendy Lin, MD, PhD
Researcher Spotlight: Wen-Hsuan Wendy Lin, MD, PhD COLUMBIA UNIVERSITY Peripheral T-cell lymphomas (PTCL) represent a group of aggressive blood cancers with poor outcomes. A common phenomenon in PTCL is the development of a proinflammatory microenvironment, in which lymphoma cells recruit…
Andrew Jallouk, MD, PhD
Researcher Spotlight: Andrew Jallouk, MD, PhD VANDERBILT UNIVERSITY MEDICAL CENTER Errol M. Cook Memorial Scholar Chimeric antigen receptor (CAR) T-cell therapy represents a highly effective treatment option for many types of lymphoma. Currently available CAR T-cell therapies are engineered on…
Alexander Boardman, MD
Researcher Spotlight: Alexander Boardman, MD MEMORIAL SLOAN KETTERING Dobosh Family Scholar Treatment of lymphoma has been revolutionized by the emergence of CD19-directed chimeric antigen receptor (CAR) T-cell therapies, but many patients still relapse after treatment. Dr. Boardman’s LRF research seeks…
Ajilan Al Zaki, MD, PhD
Researcher Spotlight: Ajilan Al Zaki, MD, PhD MD ANDERSON CANCER CENTER Chimeric antigen receptor (CAR) T-cell therapies represent a meaningful treatment option for lymphoma, but many patients who receive these therapies will experience side effects caused by inflammation. In some…
Timothy Voorhees, MD
Researcher Spotlight: Timothy Voorhees, MD THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE Schroder Family Scholar Post-transplant lymphoproliferative disorders (PTLD) are an aggressive group of lymphomas that occur in the setting of immunosuppression after solid organ transplant. There are very few…
Christine Ryan, MD
Researcher Spotlight: Christine Ryan, MD DANA-FARBER CANCER INSTITUTE Kanti R. Rai, MD Clinical Scholar Richter’s transformation (RT) represents a devastating progression of chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) into an aggressive B-cell lymphoma. Prognosis with RT is…
Swetha Kambhampati, MD
Researcher Spotlight: Swetha Kambhampati, MD CITY OF HOPE COMPREHENSIVE CANCER CENTER Eric Cohen Distinguished Scholar Patients with diffuse large B cell lymphoma (DLBCL) who experience relapse after chimeric antigen receptor (CAR) T cell therapy have limited treatment options, and there…